🇺🇸 FDA
Patent

US 9987233

Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

granted A61KA61K31/56A61K31/58

Quick answer

US patent 9987233 (Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith) held by Eupraxia Pharmaceuticals USA LLC expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Eupraxia Pharmaceuticals USA LLC
Grant date
Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/56, A61K31/58, A61K9/0024, A61K9/5026